604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III

DYRK1A interacts with EZH2 to regulate transcriptionally active chromatin in myeloid leukemia associated with down syndrome

BTK regulates EZH2 stability in myeloid leukemia associated with down syndrome

Adaptive rebalancing of ROS composition averts LSD1 inhibitor–induced oxidative stress in AML

Single‑cell analysis of BAX responses reveals venetoclax sensitivity and enables development of BAX‑targeting combinations in AML

Distinct mTOR and CDK1 regulated translation circuits sustain FLT3 mutated AML survival under therapy

BPI 2358 reprograms immunosuppressive macrophages and impairs leukemic progression in MN1 overexpressing AML In Vivo

METTL3 inhibition disrupts R loop homeostasis and activates the cgas sting pathway in Acute Myeloid Leukemia

Co targeting menin and RAS in KMT2A r NPM1c AML with activated RTK RAS MAPK signaling

Anti leukemic efficacy of a novel inhibitor for KMT2A r FLT3 driven AML via multi kinase targeting and synergy with menin inhibition

TGM2 as a novel therapeutic target in venetoclax resistant AML Disrupting histone serotonylation driven mitophagy with nanoparticle delivered inhibitors

Synergistic correction of polycythemia vera phenotype via dual targeting of JAK2 and Gas6 in Jak2 exon 12 mutant mice

Inhibition of Drp1 a mitochondrial fission GTPase disrupts mitochondrial quality control and impairs stem like properties in Acute Myeloid Leukemia

Preclinical efficacy of dual BET HAT inhibitor–based combinations against post myeloproliferative neoplasm secondary AML cells

CD123 targeted radiotheranostics of Acute Myeloid Leukemia with 89Zr 177Lu labeled pivekimab

ORM 1153 A CD123 targeting degrader antibody conjugate with GSPT1 degrading payload exhibits potent preclinical antitumor activity in Acute Myeloid Leukemia

FLT3 F691L confers kinase independent resistance via Grb2 dependent MAPK signaling in AML

CBX–663 a novel TCR mimetic T cell engager targeting a telomerase reverse transcriptase TERT peptide HLA complex that exhibits potent efficacy against AML cells

Bioequivalence of ruxolitinib once daily extended release vs twice daily immediate release tablets in healthy adults

First in human randomized placebo controlled Phase 1 study of RPT1G a novel hyperbolic NAMPT inhibitor for use in acute leukemias Safety pharmacokinetics and pharmacodynamics in healthy volunteers

The impact of NR1I2 gene polymorphism and body weight on asciminib pharmacokinetics in patients with chronic myeloid leukemia